- Home
- PLRX vs PCRX Comparison
PLRX vs PCRX Comparison
Compare PLRX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- PCRX
- Stock Information
- Founded
- PLRX 2015
- PCRX 2006
- Country
- PLRX United States
- PCRX United States
- Employees
- PLRX N/A
- PCRX N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- PCRX Health Care
- Exchange
- PLRX Nasdaq
- PCRX Nasdaq
- Market Cap
- PLRX 84.7M
- PCRX 1.2B
- IPO Year
- PLRX 2020
- PCRX 2011
- Fundamental
- Price
- PLRX $1.16
- PCRX $24.02
- Analyst Decision
- PLRX Hold
- PCRX Buy
- Analyst Count
- PLRX 10
- PCRX 9
- Target Price
- PLRX $9.79
- PCRX $29.89
- AVG Volume (30 Days)
- PLRX 1.4M
- PCRX 526.9K
- Earning Date
- PLRX 08-06-2025
- PCRX 07-29-2025
- Dividend Yield
- PLRX N/A
- PCRX N/A
- EPS Growth
- PLRX N/A
- PCRX N/A
- EPS
- PLRX N/A
- PCRX N/A
- Revenue
- PLRX N/A
- PCRX $702,772,000.00
- Revenue This Year
- PLRX N/A
- PCRX $7.54
- Revenue Next Year
- PLRX N/A
- PCRX $10.78
- P/E Ratio
- PLRX N/A
- PCRX N/A
- Revenue Growth
- PLRX N/A
- PCRX 3.08
- 52 Week Low
- PLRX $1.10
- PCRX $11.16
- 52 Week High
- PLRX $16.10
- PCRX $29.33
- Technical
- Relative Strength Index (RSI)
- PLRX 34.14
- PCRX 36.83
- Support Level
- PLRX $1.23
- PCRX $23.85
- Resistance Level
- PLRX $1.43
- PCRX $25.16
- Average True Range (ATR)
- PLRX 0.11
- PCRX 0.79
- MACD
- PLRX -0.02
- PCRX -0.12
- Stochastic Oscillator
- PLRX 3.92
- PCRX 8.20
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.